AI/ML Innovations Inc. (AIML) has appointed Dr. Martin Stephen Green, a distinguished Professor Emeritus at the University of Ottawa, to its Medical Advisory Board. This appointment, effective April 27, 2026, is expected to bolster AIML's clinical capabilities as it develops its AI-powered electrocardiogram (ECG) technology.
Dr. Green brings over 45 years of expertise in cardiac electrophysiology, having founded the Arrhythmia Service at the University of Ottawa Heart Institute in 1983. His extensive background includes leadership roles in various clinical programs and involvement in foundational research in cardiac care. He has collaborated closely with Dr. Paul Dorian, the Medical Innovation Architect at AIML, further enhancing the advisory board's qualifications.
The inclusion of Dr. Green is viewed as pivotal for AIML as the company seeks to advance its clinical validation and regulatory strategies. Dr. Dorian noted that Dr. Green's contributions will significantly impact the company’s growth trajectory in the digital health sector.
In conjunction with the appointment, AIML has granted 4,000,000 stock options to employees, each exercisable for a common share at a price of $0.10 for the next five years. This move aims to align employee interests with the company’s strategic goals, promoting a dedicated workforce as AIML expands its innovative healthcare solutions.
AIML specializes in leveraging artificial intelligence and neural networks to enhance digital health technologies, particularly in transforming biometric data into actionable clinical insights aimed at improving patient diagnosis and treatment options.
Dr. Martin Green, a highly respected figure in Canadian cardiac electrophysiology, has been appointed to AIML's Medical Advisory Board. His extensive experience and contributions to the field are likely to enhance AIML's clinical strategies as the company advances its product portfolio.
Dr. Green's appointment is seen as a pivotal moment for AIML, considering his vast expertise in electrocardiography and clinical research. His role is expected to bolster AIML's efforts in clinical validation and regulatory engagement.
Dr. Green is a Professor Emeritus at the University of Ottawa with a distinguished career spanning over 45 years in cardiac electrophysiology. His academic and clinical achievements provide AIML with substantial expertise as it seeks to innovate in the digital health sector.
The Medical Advisory Board was established to guide AIML's clinical studies, regulatory strategies, and deployment of AI-driven ECG platforms. The inclusion of experts like Dr. Green enhances the board's capability in these critical areas.
AIML has granted 4,000,000 stock options to employees, exercisable at $0.10 per share for a period of five years. This move aims to align employee interests with the company's growth objectives.
AIML is pioneering the use of artificial intelligence and neural networks to enhance digital health, aiming to convert complex biometric data into actionable insights for improved diagnosis and patient care.
Given Dr. Green's profound experience in healthcare and his commitment to advancing cardiac care, his involvement could significantly influence AIML's research and development efforts, potentially leading to breakthroughs in ECG technology.
Dr. Paul Dorian, as the Chair of the Medical Advisory Board, will work alongside Dr. Green to shape the direction of AIML's clinical initiatives, ensuring that they are aligned with both scientific standards and market needs.